# (C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis

> **NCT02047604** · PHASE2 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 41 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** SAN-300 0.5 mg/kg QW
- **DRUG:** SAN-300 1.0 mg/kg QW
- **DRUG:** SAN-300 2.0 mg/kg QOW
- **DRUG:** SAN-300 4.0 mg/kg QOW
- **DRUG:** SAN-300 4.0 mg/kg QW
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02047604
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2017-02-23
- **Final completion:** 2017-03-23
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2021-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02047604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02047604, "(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02047604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*